Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

A number of other equities analysts have also recently weighed in on the company. Zacks Investment Research upgraded Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Morgan Stanley began coverage on Biohaven Pharmaceutical Holding Co in a report on Wednesday, May 31st. They issued an “overweight” rating for the company. William Blair began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “outperform” rating and a $46.00 price target for the company. Needham & Company LLC began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Piper Jaffray Companies began coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 price target for the company. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 38.12 on Thursday. The company has a 50-day moving average of $29.28 and a 200 day moving average of $25.82. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $38.56. The firm’s market cap is $1.37 billion.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Upgrades Biohaven Pharmaceutical Holding Co Ltd (BHVN) to Strong-Buy” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/09/bidaskclub-upgrades-biohaven-pharmaceutical-holding-co-ltd-bhvn-to-strong-buy.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.